| Objective: Recently, cerebral infarction, of which the incidence, mortality, morbidity and recurrence rate is higher than other diseases, endangers human health. With the rapid development of economy and the changes of residents’ lifestyle, an increasing number of patients suffer from cerebral infarction every year. In China, the number of new stroke patients reaches 1.5 million~2 million annually, among them, 70% are diagnosed with cerebral infarction. Besides, patients tend to be younger, which pose adverse impacts on people’s life. Butylphthaliad, as a new drugs for cerebral infarction treatment, can block multiple pathophysiological stages of cerebral infarction, reducing cerebral injury and improving the prognosis. Vascular endothelial growth factor(VEGF) is a kind of highly specifid endothelial cell mitogen with many biological activities. With the up-regulation of VEGF, vascular endothelial cell proliferation and formation can be promoted, increasing the biological function of vascular permeability.Some experiments have proved that Butylphthaliad facilitate the formation of new blood vessels and collateral circulation, which was related to VEGF up-regulation. This study is designed to provide evidence about the cerebral protection of butypathaliad by observing the effects of butylphthaliad sodium chloride injection on the neurological function and the level of vascular endothelial growth factor in patients with cerebral infarction.Methods :All 82 patients enrolled were diagnosed with acute cerebral infarction according to infarction diagnostic criteria of the Fourth National Stroke Conference in 1995. They hospitalized in the department of internal neurology of the Second Hospital of Hebei Medicine University from October 2013 to October 2014. All the patients were checked with cranial CT or MRI and were randomly divided into controlled group(n=40) and treatment group(n=42).The onset time of the patients from falling ill to going to hospital is within 48 hours.The patients in controlled group received routine treatment for 14 days, including platelet aggregation inhibition, statins, radical elimation, neurons protection, blood pressure and blood glucose regulation and sympomatic treatment. Besides routine treatment, the patients in treatment group received Butylphthaliad 100 ml/time, 2 times/day for 14 days. On the 7th and 14 th day of treatment, the degree of neurological impairment were evaluted with NIHSS score. The reduction rate and effective rate were calculated according to the NIHSS score. All patients’ blood sample were taken from median cubital veins in early morning before treatmenton 7th and 14 th day of treatment and get centrifuged on 3000r/min for 10 min after 3 hours of sample-taking. Serum sample was kept on-70℃. The levels of VEGF in serum were measured by standard quantitative sandwich ELISA.All data were analysed by using 17.0 SPSS. Using χ2 test to compare the count data between two groups.The measurement data was shown as mean ± standard deviation( x ±s) and the comparison between two groups was used by two-sample t-test.The repeated measurement data within group and between groups was compared using repeated measures analysis of variance.Define P value of less than 0.05 as significant.Results:1 The general data General data including sex, age,onset time, history of hypertension, diabetes, coronary heart disease and so on showed no significant difference(P>0.05) between two groups.2 The NIHSS score Before treatment, the NIHSS score of controlled and treatment group were(8.50±3.07) and(8.21±3.58). The NIHSS score showed no significant difference between two groups(P>0.05). After 7 days treatment, the NIHSS score were(7.78±2.84)and(6.02±2.45)in controlled and treatment group. After 14 days treatment, the NIHSS score were(6.27±2.56) and(4.64±2.20) in controlled and treatment group. The NIHSS score of two groups decreased after 7 days and 14 days treatment, and it showed significant difference(P<0.05). While the NIHSS score decreased more significantly in treatment group than that in controlled group at the 7th and the 14 th day after treatment(P<0.05).3 The effective rate In controlled group, the reduction rate of NIHSS score were(8.38±14.51)% and(25.92±24.15)% at the 7th day and the 14 th after treatment. In treatment group, the reduction rate of NIHSS score were(24.21±15.78)% and(39.18±25.23). The reduction rate in treatment group was higher than that in controlled group, and it showed significant difference between two groups(P<0.05). After 14 days treatment, the effective rate of controlled group and treatment group were 62.50% and 83.33%. The effective rate in treatment group was higher than that in the controlled group, and it showed significant difference(P<0.05).4 The level of VEGF before treatment, the level of VEGF was(0.218±0.061) in controlled group and(0.210±0.070)pg/ml in treatment group, and it showed no significant difference(P>0.05). In controlled group, the levels of VEGF was(0.316±0.059)pg/ml at the 7th day and(0.264±0.059)pg/ml at the 14 th day after treatment. In the treatment group, the levels of VEGF was(0.362±0.050)pg/ml and(0.305±0.054)pg/ml. After 7 days and 14 days of treatment, the levels of VEGF increased significantly in two groups(P<0.05). While the levels of VEGF increased more significantly in the treatment group than that in the controlled group(P<0.05).Conclusions:1 Butylphthaliad sodium chloride injection could significantly alleviate impairment of neurological function and improve the effect of treatment.2 Butylphthaliad sodium chloride injection could significantly increase the expression of VEGF in patients with cerebral infarction,promoting the formation of new blood vessels and protecting the function of neurons. |
PDF Full Text Request